Developmental Toxicity Evaluation of the Dietary Supplement Vinpocetine Using Mouse and Human 3D Gastruloids.

Our assessment

This 2026 study investigated the potential developmental risks of the dietary supplement vinpocetine, which is often sold for cognitive enhancement. Researchers used both mouse and human 3D gastruloids—lab-grown cell structures that mimic early embryo development—to test vinpocetine's effects. The study was designed to assess whether animal-based concerns about vinpocetine's impact on embryonic development apply to human biology. Data not available on sample size or study duration.

How it works

Vinpocetine is marketed to improve mental function, but the FDA has previously warned against its use by people of childbearing potential due to animal studies showing it can impair embryonic development FDA FAERS ↗. This study used advanced lab models to directly compare its effects on mouse and human development. The key finding is that vinpocetine disrupted normal development in both mouse and human gastruloids, suggesting the risks seen in animals may also apply to humans. What this means for you: if you are pregnant, planning to become pregnant, or could become pregnant, the data supports the FDA's warning to avoid vinpocetine entirely.

Safety profile

Data not available on FDA adverse event reports for vinpocetine specifically. The study's findings from lab models indicate a risk to early embryonic development, aligning with the FDA's public warning that vinpocetine use should be avoided by individuals of childbearing potential FDA FAERS ↗.

Our recommendation

Based on this 2026 study using advanced lab models, the evidence suggests vinpocetine may pose a risk to human embryonic development. If you are of childbearing potential, do not take vinpocetine. For others, consult a healthcare provider before use, as the supplement lacks comprehensive safety testing FDA FAERS ↗.